Maximilian von Eynatten

Maximilian von Eynatten

UNVERIFIED PROFILE

Are you Maximilian von Eynatten?   Register this Author

Register author
Maximilian von Eynatten

Maximilian von Eynatten

Publications by authors named "Maximilian von Eynatten"

Are you Maximilian von Eynatten?   Register this Author

80Publications

1864Reads

9Profile Views

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.

Diabetes Obes Metab 2019 Nov 26;21(11):2465-2473. Epub 2019 Aug 26.

TA CardioMetabolism, Boehringer Ingelheim International GmbH, Biberach, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13829DOI Listing
November 2019

Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.

Nephrol Dial Transplant 2019 Sep 8. Epub 2019 Sep 8.

Department of Medicine, Würzburg University Clinic, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfz179DOI Listing
September 2019

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Am J Kidney Dis 2019 Jun 26. Epub 2019 Jun 26.

Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia; Boehringer Ingelheim International GmbH, Ingelheim; Department of Medicine, Würzburg University Clinic, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2019.03.432DOI Listing
June 2019

Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.

Proteomics Clin Appl 2019 03 28;13(2):e1800144. Epub 2019 Jan 28.

Boehringer Ingelheim International GmbH. KG, Binger Str. 173, 55216, Ingelheim am Rhein, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prca.201800144DOI Listing
March 2019

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.

Diabetes Care 2018 08 25;41(8):e129-e130. Epub 2018 Jun 25.

Department of Physiology and Division of Nephrology, Department of Medicine, and Banting & Best Diabetes Centre, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc18-0394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054503PMC
August 2018

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Circulation 2018 01 13;137(2):119-129. Epub 2017 Sep 13.

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada (B.Z.) and Division of Endocrinology, University of Toronto, Canada (B.Z.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028268DOI Listing
January 2018

Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.

Diabetologia 2017 06;60(6):1159-1160

Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, 585 University Ave, 8N-845, Toronto, ON, Canada, M5G 2N2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00125-017-4241-3DOI Listing
June 2017

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

N Engl J Med 2016 Jul 14;375(4):323-34. Epub 2016 Jun 14.

From the Department of Medicine, Division of Nephrology, Würzburg University Clinic, Würzburg (C.W.), and Boehringer Ingelheim Pharma, Ingelheim (M.E., M.M., H.J.W., U.C.B.) - both in Germany; the Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.); the Biostatistics Center, George Washington University, Rockville, MD (J.M.L.); the Divisions of Cardiology (D.F.) and Endocrinology (B.Z.), University of Toronto, and the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital (B.Z.) - both in Toronto; and Boehringer Ingelheim Norway, Asker, Norway (O.E.J.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1515920DOI Listing
July 2016

Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.

Diab Vasc Dis Res 2015 Jul 4;12(4):249-57. Epub 2015 May 4.

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1479164115579001DOI Listing
July 2015

Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes.

Acta Diabetol 2014 24;51(3):479-89. Epub 2013 Dec 24.

Department of Medicine 1 and Clinical Chemistry, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00592-013-0542-2DOI Listing
January 2015

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.

Diabetologia 2014 Dec 4;57(12):2599-602. Epub 2014 Oct 4.

Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, 585 University Ave, 8N-845, Toronto, ON, Canada, M5G 2N2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00125-014-3396-4DOI Listing
December 2014

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.

Kidney Int 2014 Nov;86(5):1057-8

Kidney Research Centre, Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ki.2014.246DOI Listing
November 2014

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Circulation 2014 Feb 13;129(5):587-97. Epub 2013 Dec 13.

Department of Medicine, Division of Nephrology (D.Z.I.C., M.M., V.L., A.L.) and the Department of Medicine, Division of Endocrinology (B.A.P.), Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; Boehringer Ingelheim Canada Ltd./Ltée, Burlington, Ontario, Canada (N.S.); Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT (N.M.F., M.v.E.); and Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany (H.J.W., O.E.J., U.C.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005081DOI Listing
February 2014

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.

Diab Vasc Dis Res 2014 Jan 29;11(1):34-40. Epub 2013 Oct 29.

Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1479164113507068DOI Listing
January 2014

Linagliptin for elderly patients with type 2 diabetes - Authors' reply.

Lancet 2014 Jan;383(9914):307-8

Boehringer Ingelheim, Ingelheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(14)60104-5DOI Listing
January 2014

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Cardiovasc Diabetol 2014 Jan 29;13:28. Epub 2014 Jan 29.

Division of Nephrology, University Health Network, University of Toronto, Toronto General Hospital, 585 University Ave, Toronto 8N-845, M5G 2N2, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1475-2840-13-28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915232PMC
January 2014

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.

Lancet 2013 Oct 13;382(9902):1413-23. Epub 2013 Aug 13.

Diabetes Centre, Heart of England NHS Foundation Trust, Birmingham, UK; University of Birmingham, Birmingham, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(13)61500-7DOI Listing
October 2013

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.

Cardiovasc Diabetol 2013 Apr 9;12:60. Epub 2013 Apr 9.

Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, P,O, Box 368, Ridgefield, CT 06877, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1475-2840-12-60DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626685PMC
April 2013

Comparing aortic stiffness in kidney transplant recipients, hemodialysis patients, and patients with chronic renal failure.

Clin Transplant 2011 Jul-Aug;25(4):E463-8. Epub 2011 Apr 26.

Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1399-0012.2011.01462.xDOI Listing
January 2012

MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men.

Eur J Clin Invest 2011 Dec 4;41(12):1261-7. Epub 2011 May 4.

Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2362.2011.02530.xDOI Listing
December 2011

Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease.

Am J Cardiol 2010 Jun 27;105(12):1666-72. Epub 2010 Apr 27.

Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2010.01.342DOI Listing
June 2010

Non-diabetic chronic kidney disease influences retinal microvasculature.

Kidney Blood Press Res 2009 7;32(6):428-33. Epub 2009 Dec 7.

Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000264650DOI Listing
April 2010

Pulsatile stress correlates with (micro-)albuminuria in renal transplant recipients.

Transpl Int 2010 Mar 12;23(3):292-8. Epub 2009 Oct 12.

Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1432-2277.2009.00981.xDOI Listing
March 2010

Retinol-binding protein 4 & atherosclerosis: risk factor or innocent bystander?

Atherosclerosis 2009 Sep 6;206(1):38-9. Epub 2009 May 6.

Department of Nephrology, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2009.04.038DOI Listing
September 2009

Fetuin-A and arterial stiffness in patients with normal kidney function.

Regul Pept 2009 Apr 13;154(1-3):39-43. Epub 2008 Dec 13.

Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.regpep.2008.12.001DOI Listing
April 2009

Comparison of immunoassays for the selective measurement of human high-molecular weight adiponectin.

Clin Chem 2009 Mar 23;55(3):568-72. Epub 2009 Jan 23.

Department of Nephrology, Technische Universitaet Muenchen, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2008.112425DOI Listing
March 2009

Altered molecular weight forms of adiponectin in hypertension.

J Clin Hypertens (Greenwich) 2009 Jan;11(1):11-6

Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1751-7176.2008.00057.xDOI Listing
January 2009

High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men.

Atherosclerosis 2008 Jul 19;199(1):123-8. Epub 2007 Nov 19.

Department of Nephrology, Technical University Munich, Ismaningerstr. 22, 81675 Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2007.10.002DOI Listing
July 2008

Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease.

Eur Heart J 2008 May 5;29(10):1307-15. Epub 2008 Apr 5.

Department of Medicine I and Clinical Chemistry, Ruprecht-Karls-University of Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehn135DOI Listing
May 2008

Retinol-binding protein-4 in experimental and clinical metabolic disease.

Expert Rev Mol Diagn 2008 May;8(3):289-99

Department of Nephrology, Technical University of Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/14737159.8.3.289
Publisher Site
http://dx.doi.org/10.1586/14737159.8.3.289DOI Listing
May 2008

Association of lipopolysaccharide-binding protein and coronary artery disease in men.

J Am Coll Cardiol 2007 Jul 18;50(1):25-31. Epub 2007 Jun 18.

Department of Intensive Care Medicine, University Hospital of Bern (Inselspital), Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2007.02.070DOI Listing
July 2007

Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease.

Clin Chem 2006 May 23;52(5):853-9. Epub 2006 Mar 23.

Department of Medicine I (Endocrinology and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2005.060509DOI Listing
May 2006

The role of adiponectin in atherosclerosis: do lipids tip the scales?

Future Cardiol 2005 Nov;1(6):775-84

University of Heidelberg, Department of Medicine I (Dept. of Endocrinology & Metabolism), INF 410, D-69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/14796678.1.6.775
Publisher Site
http://dx.doi.org/10.2217/14796678.1.6.775DOI Listing
November 2005

Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo.

Diabetes Care 2005 Sep;28(9):2181-6

Department of Medicine I (Endocrinology and Metabolism), Ruprecht-Karls-University of Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/diacare.28.9.2181DOI Listing
September 2005

A mechanism converting psychosocial stress into mononuclear cell activation.

Proc Natl Acad Sci U S A 2003 Feb 10;100(4):1920-5. Epub 2003 Feb 10.

Department of Medicine I, University of Heidelberg, Otto-Meyerhof-Zentrum, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0438019100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC149934PMC
February 2003